• About Breast Cancer Trials
  • Our Research
  • Research Results
  • Our People
  • Our Supporters
  • Financials
  • How You Can Help

How You Can Help

Recent Posts

  • Dr Sheridan Wilson
  • Associate Professor Nicholas Wilcken
  • Professor Andrew Spillane
  • Professor Christobel Saunders AO
  • Ms Marg O’Donnell AO

Recent Comments

No comments to show.
ABOUT BREAST CANCER TRIALS

Who We Are

Chair And CEO Report

Strategic Plan

Breast Cancer Today

Our Impact

OUR RESEARCH

What Is A Clinical Trial

The Year In Review

Director Of Research Report

2022-2026 Research Strategy

Our Clinical Trials

Participating Institutions & International Collaborators

2023 Clinical Fellowships & International Fellowship Support

Discretionary Funding

43rd Annual Scientific Meeting & Awards

RESEARCH RESULTS

Overview

Assessing the effect of breast cancer treatment on ovarian function

Blocking cell division helps with breast cancer relapse in older women

Breast MRI may allow some patients to safely avoid radiation therapy

New options for triple negative breast cancer patients

Olaparib increases survival for early breast cancer patients with BRCA1/2 gene mutations

Repurposing a common reflux drug to ease chemotherapy nausea

Suppressing ovarian function increases breast cancer survival in high-risk premenopausal women

Treatment simplified – no need to start hormonal therapy alongside chemotherapy

OUR PEOPLE

Board Of Directors

Committees

Consumer Advisory Panel

Our Staff

 

OUR SUPPORTERS

Individual Givers

Community Activists

Corporate & Foundation Partners

FINANCIALS

Our Financials

HOW YOU CAN HELP

Become a Member

Participate in a Clinical Trial

Your Support Can Save Lives

Contact Us  • Disclaimer  •  Privacy Policy  •  Glossary

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Copyright © 2023 ANZ Breast Cancer Trials Group Ltd | ABN 64 051 369 496